Nexus Pharms Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for NEXUS PHARMS, and what generic alternatives to NEXUS PHARMS drugs are available?
NEXUS PHARMS has fifteen approved drugs.
There are four US patents protecting NEXUS PHARMS drugs. There is one tentative approval on NEXUS PHARMS drugs.
There are eight patent family members on NEXUS PHARMS drugs in eight countries and seventy-four supplementary protection certificates in eight countries.
Summary for Nexus Pharms
| International Patents: | 8 |
| US Patents: | 4 |
| Tradenames: | 17 |
| Ingredients: | 15 |
| NDAs: | 15 |
Drugs and US Patents for Nexus Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexus Pharms | TESTOSTERONE ENANTHATE | testosterone enanthate | INJECTABLE;INJECTION | 040575-001 | Jun 14, 2006 | AO | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Nexus Pharms | EMERPHED | ephedrine sulfate | SOLUTION;INTRAVENOUS | 213407-001 | Apr 17, 2020 | RX | Yes | Yes | 11,090,278 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Nexus Pharms | COLISTIMETHATE SODIUM | colistimethate sodium | INJECTABLE;INJECTION | 065177-001 | Mar 19, 2004 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nexus Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 113825500 | ⤷ Try a Trial |
| Canada | 3140043 | ⤷ Try a Trial |
| South Korea | 20220009985 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Nexus Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1856135 | LUC00153 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: FOSTAMATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, OU UN HYDRATE, SOLVATE OU N-OXYDE DE FOSTAMATINIB OU LE SEL PHARMACEUTIQUEMENT ACCEPTABLE DE FOSTAMATINIB, EN PARTICULIER FOSTAMATINIB DISODIUM, EVENTUELLEMENT SOUS FORME D'HYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/19/1405 20200113 |
| 1856135 | SPC/GB20/016 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTERED: UK EU/1/19/1405 (NI) 20200113; UK PLGB 12930/0022 20200113; UK PLGB 12930/0023 20200113 |
| 1441735 | SPC/GB08/020 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
